Xiang Qian

HCMC.. 、, 、 、. 4, 1, 3. 100, SCI 80, JACC、STTT、Pharmacol Ther、Stroke、AJPS,. “ ”,“ ”,. 1.:PEAR1,:82274024,. 2. 、,:2022ZXJ02C02-1,:,:2023.1-2026.12,. 3.:PEAR1,:81973395,. 4. “ ”:,:2017ZX09304028-006,. 5.: PEAR1,:81673509,. 6.: GPIIb/IIIa ”,:81202592,. 7.:,:2016YFSF090494,. 2021 “ ”,,, 5/ 19 2015   2014 “ ”,,, 2/ 7 2013   2012 “ ”,,, 4/ 4 1)Li W, Zhang H, Xiang Q*, Cui Y. Does repeat revascularization introduce bias for reducing mortality in antiplatelet therapy group? J Am Coll Cardiol 2021 Nov 16;78(20):e171. (Corresponding author) Q1, IF 24.00 2)Pang X, He X, Qiu Z, Zhang H, Xie R, Liu Z, Gu Y, Zhao N, Xiang Q*, Cui Y*. Targeting integrin pathways: mechanisms and advances in therapy. Signal Transduct Target Ther. 2023 Jan 2;8(1):1. doi: 10.1038/s41392-022-01259-6. (Co-corresponding author) Q1, IF 39.3 3)Xiang Q, Pang X, Liu Z, Yang G, Tao W, Pei Q, Cui Y. Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic. Pharmacol Ther. 2019;203:107393. Q1, IF 13.5 4)Xiang Q, Wu W, Zhao N, Li C, Xu J, Ma L, Zhang X, Xie Q, Zhang Z, Wang J, Xu W, Zhao X, Cui Y. The influence of genetic polymorphisms in drug metabolism enzymes and transporters on the pharmacokinetics of different fluvastatin formulations. Asian J Pharm Sci. 2020;15(2):264-272. Q1, IF 10.2 5)Xiang Q#, Wang Z#,  Mu G, Xie Q, Liu Z, Zhou S, Zhang H, Wang Z, Jiang J, Hu K, Zhang Y, Zhao Z, Yuan D, Guo L, Wu T, Zhang J, Wang N, Xiang J, Gu Z, Sun J, Cui Y*. Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study. Clin Transl Med. 2023;13(5):e1263. Q1, IF 10.6 6)Xiang Q#, Xie Q#, Liu Z, Mu G, Zhang H, Zhou S, Wang Z, Wang Z, Zhang Y, Zhao Z, Yuan D, Guo L, Wang N, Xiang J, Song H, Sun J, Jiang J, Cui Y. Genetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese patients with nonvalvular atrial fibrillation: A nationwide multicentre prospective cohort study[J]. Clin Transl Med, 2022, 12(12): e1104. Q1, IF 10.6 7)Liu Z, Xiang Q*, Zhao X, Wang Z, Mu G, Xie Q, Zhou S, Chen S, Hu K, Xu J, Ma L, Cui Y. Candidate gene and pathway analyses identifying genetic variations associated with prasugrel pharmacokinetics and pharmacodynamics. Thromb Res. 2018;173:27-34. (Corresponding author) Q1, IF 7.5 8)Xiang Q, Zhang HX, Wang Z, Liu ZY, Xie QF, Hu K, Zhang Z, Mu GY, Ma LY, Jiang J, Cui YM. The predictive value of circulating microRNAs for venous thromboembolism diagnosis: A systematic review and diagnostic meta-analysis. Thromb Res. 2019 Sep;181:127-134. Q1, IF 7.5